Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
75% inpatient admissions increase in 2023, 8% outpatient increase with new Myrtle Recovery outpatient services only just beginning in Novemeber. When you factor what the Forbes article says about fixed cost reimbursement, you get $2-3 million earnings on $20-22 million revenues minimum. Cost of revenue ratio can only improve with revenue increases.
Current P/E @ .0001 between 1.5 and 2, maybe lower.
Minimum estimate: $2-3 million earnings on $20-22 million revenue. Certainty in forward earnings:
https://www.forbes.com/sites/gebai/2024/01/21/rural-urban-healthcare-access-gap-its-all-about-the-fixed-costs/?sh=45df4b676288
Forbes has taken an interest. There can't be many rural critical access hospital companies listed on any exchange. This article goes right at why I have so much confidence in RNVA forward revenue and earnings:
https://www.forbes.com/sites/gebai/2024/01/21/rural-urban-healthcare-access-gap-its-all-about-the-fixed-costs/?sh=f8412556288f
With you on that.
I've been playing with some numbers based on what we know (75% increase in inpatient admissions in 2023, swingbed revenues increasing, new Myrtle Recovery Center revenue beginning to come in against the costs that showed in Q3). The most conservative Q4 estimates have RNVA closing 2023 at over $20 million with a profit of at least two million. At .0001, that's a P/E of 2/1. At a bare minimum, we know we can $2 million to the bottom line in 2024 in interest savings from debt paid off or restructured plus Myrtle Recovery revenue increases through most if not all of the year, not to mention any continued growth from existing services.
We also know the OS has not changed for nearly three months and, according to the recently filed amendment to the insider trading plan/prospectus, the holder of those Series B Preferred Shares is no longer required to sell, but if they sell, they still have to sell at .00014 until the stock is uplisted to OTCQX or Nasdaq. That indicates that upon conversion the investor is holding common shares instead of selling and RNVA is kept a standing corporate buyback offer at .00014. Corporate buybacks are not subject to the SEC's insider trading plan reporting requirement. We're out of major .0001 sellers.
I have never been more confident in a 000 stock in my 30 years of f***king with them.
No red paint to close a holiday shortened week. Just my opinion, but I think next week will be big.
https://www.sec.gov/news/press-release/2023-234
Fox guarding the hen house, or someone who knows where the skeletons are buried?
So were tulip bulbs in the early 1600s. Wouldn't have bought those either if I had been around then.
Might get a short term bounce if your timing is right, but long term, obviously not. Oil companies have not added new refinery capacity for decades, because they know it would be a lousy long term investment.
I'm more concerned about the fallout when the bottom falls out of the crypto market. The bottom will fall out. It's inevitable. Tulip bulbs have more fundemental value.
Congress would have to do that. Don't fall for the propaganda funded by the same people who fund congressional campaigns of both parties. Blaming Gensler is too easy an out for them.
Too many in Congress don't have the balls to regulate markets and have fought Gensler on every regulation he does have the authority to implement, expecially regulations that protect small investors.
Gensler would shut down crypto if he had the legislative authority.
I have 30 years of experience and a growing list of successful OTC investments. Sorry that bores you. If staring at a ticker is entertaining to you, have at it. There are plenty of others to choose from.
All beginners are dumbasses. I was too. Some are willing and able to learn from others and from experience. Some just go on being dumbasses.
They should tell you how annoying your posts are, especially to those of us who post relevant, if not useful, information only to see it overposted by stupid stuff about a "ticker."
Nobody can tell you anything, because it's all way over your head.
Your posts are worthless.
So? Nothing to do with this situation. I read earnings reports. I never base my investment decisions on anyone's advice. At most, I might do my DD on a stock because isome4one I trust recommends it.
Funny how you didn't chime in when we saw the uptick on good volume this morning, only when trading slowed. "Pumpers?" What does that make you when you only chime in when "the ticker" gives you a chance to discourage buyers. The truth is, you don't have a clue why any ticker does what it does at any particular moment, because you don't understand the mechanics of it any more than you understand valuation. The OS has not changed for nearly three months. This is to educate you on why "the ticker" has done what it has been doing of late:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173657576
Your comparable is a fictional ticker from a movie? Good strategy.
.0002 buys within hours or days, not weeks IMO.
I will maintain a heavy position in RNVA at least until it is well above the 000s. I still plan to set my price targets based on the forward P/E. Nothing crazy, but a mid to long term target in the pennies or higher based on forward P/E is quite plausable.
Yep, what's yours?
RNVA tops the OTC most active list. And not a peep from Diggity. He must be standing by hoping for a downtick to report out.
The remaining .0001 sellers are making a big mistake.
And how is that pertinent?
Nope, this is what has been happening for going on three months:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173657576
Since no later than November 6, the buyer(s) on all downticks below .0001 was either a commercial investor accumulating, an insider buying, or the corporation buying back insider shares at the conversion price of .00009 or better). How do we know that? Because those trades must me done through the transfer agent, meaning buyers and sellers below .0001 must hold or receive the physical stock certificates.
"As of November 6, 2023, the registrant had 40,551,322,257 shares of its Common Stock, $0.0001 par value, outstanding." (10-Q filed 11/14/23)
"There were 40,551,322,257 shares of our common stock outstanding as of January 8, 2024." (Prospectus/insider trading plan amendment filed 01/11/24)
We're there already.
There are always a few who lose patience or lose faith. By the same token, it doesn't make sense for a large investor (retail, commercial, insider, or corporate buyback) to stack the bid until all the impatient money is squeezed out of the weak little hands.
Genesis and Pixleworks were both Nasdaq listed with good earnings when they merged, probably eventually acquired by a larger company. GEGI does not appear to have been any part of that.
Does someone know the full history of this company? I am wondering if it is dirived in some way from the old tech bubble company called Genesis. After the bubble burst, that company merged with a company in the same industry called Pixelworks. Never followed it after that. What is the genesis of Genesis?
Take note of the 01/11 amendmend to the insider trading plan/prospectus. If the selling shareholder holds through a QX/Nasdaq level uplisting, beautiful. If the selling shareholder decides to sell sometime in between, the selling shareholder still has to sell at .00014. The RNVA priority has been on reducing and restructuring debt, greatly improving the current balance sheet AND forward earnings. It's a dilemma though, debt reduction or buyback cheap (meaning before the stock runs). Solution: The 01/11 amendment locked in a buyback at .00014.
Another buyback? Maybe, but debt reduction should still be the priority because it fundementally adds as more shareholder value than a buyback by way of interest savings, with over $2 million per year in interest savings already generated through Q3 '23 from debt reduction and restructuring.
IHub users are just a tiny sample of the OTC market heavily skewed toward rumor mongers, momentum chasers, and short sellers.
2023 year over year: 75% increase in (CAH reimbursable) inpatient admissions. 4% increase in ER services to patients who no longer have to be transferred to a Knoxville hospital (thanks to CAH). 8% increase in outpatient services with a many times greater increase to come in 2024 from the new Myrtle Recovery Center outpatient operation. Over $2 million added to the 2024 bottom line in interest savings on debt paid off and restructured in 2023. More restructuring of debt "and other securities" ongoing. Add all that to the 2022 annual report, then subtract the first 9 months results from 2023, and you get Q4 revenue and earnings growth soaring off the chart. All this thing needs is one large investor who actually does their DD to search out the best pink sheet bargain on the board. RNVA is the no brainer of 2024.
RNVA provides health care to a "critical access" area, meaning where health care access is a critical need. "Useless company," what kind of person would say such a thing? It's a rhetorical question, so no need to answer.
Varmit, I think it's finally ready to pop.